Page 86 - 2019_07 resto del Mondo-web

T. Mährle et al.
Lenalidomide induces ubiquitination and
degradation of CK1alpha in del(5q) MDS.
Nature. 2015;523(7559):183-188.
13. Kronke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma
cells. Science. 2014;343(6168):301-305.
14. Eichner R, Heider M, Fernandez-Saiz V, et al. Immunomodulatory drugs disrupt the cere- blon-CD147-MCT1 axis to exert antitumor activity and teratogenicity. Nat Med.
2016;22(7):735-743.
15. Staffler G, Szekeres A, Schutz GJ, et al.
Selective inhibition of T cell activation via CD147 through novel modulation of lipid rafts. J Immunol. 2003;171(4):1707-1714.
16. Hu J, Dang N, Yao H, et al. Involvement of HAb18G/CD147 in T cell activation and immunological synapse formation. J Cell Mol Med. 2010;14(8):2132-2143.
17. Landskron J, Tasken K. CD147 in regulatory T cells. Cell Immunol. 2013;282(1):17-20.
18. McDaniel JM, Zou JX, Fulp W, Chen DT, List AF, Epling-Burnette PK. Reversal of T- cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation. Leukemia. 2012;26(6):1425-1429.
19. Kerdivel G, Chesnais V, Becht E, et al. Lenalidomide-mediated erythroid improve- ment in non-del(5q) myelodysplastic syn- dromes is associated with bone marrow immuno-remodeling. Leukemia. 2018;32(2): 558-562.
20. Schuler E, Giagounidis A, Haase D, et al. Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplas- tic syndromes with isolated del(5q) (LE- MON 5). Leukemia. 2016;30(7):1580-1582.
21. Mossner M, Jann JC, Nowak D, et al. Prevalence, clonal dynamics and clinical
impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the German MDS Study Group (GMDS). Leukemia. 2016;30(9):1956-1959.
22. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoprolifera- tions: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17(12):2257-2317.
23. Schliffke S, Akyuz N, Ford CT, et al. Clinical response to ibrutinib is accompanied by nor- malization of the T-cell environment in CLL- related autoimmune cytopenia. Leukemia. 2016;30(11):2232-2234.
24. Akyuz N, Brandt A, Stein A, et al. T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker. Int J Cancer. 2017;140 (11):2535-2544.
25. Bolotin DA, Poslavsky S, Mitrophanov I, et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat Methods. 2015;12(5):380-381.
26. Glanville J, Huang H, Nau A, et al. Identifying specificity groups in the T cell receptor reper- toire. Nature. 2017;547(7661): 94-98.
27. Marcou Q, Mora T, Walczak AM. High- throughput immune repertoire analysis with IGoR. Nat Commun. 2018;9(1):561.
28. Kirsch I, Vignali M, Robins H. T-cell receptor profiling in cancer. Mol Oncol. 2015;9(10):2063-2070.
29. Pielou EC. Species-diversity and pattern- diversity in the study of ecological succes- sion. J Theor Biol. 1966;10(2):370-383.
30. Schliffke S, Sivina M, Kim E, et al. Dynamic changes of the normal B lymphocyte reper- toire in CLL in response to ibrutinib or FCR chemo-immunotherapy. OncoImmunology. 2017;e1417720.
31. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibit- ing adaptive immune resistance. Nature. 2014;515(7528):568-571.
32. Riaz N, Havel JJ, Makarov V, et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell. 2017;171(4):934-949.
33. Gros A, Parkhurst MR, Tran E, et al. Prospective identification of neoantigen-spe- cific lymphocytes in the peripheral blood of melanoma patients. Nat Med. 2016;22(4): 433-438.
34. Robert L, Tsoi J, Wang X, et al. CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res. 2014;20(9):2424-2432.
35. Cha E, Klinger M, Hou Y, et al. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med. 2014;6(238):238ra270.
36. Verhelle D, Corral LG, Wong K, et al. Lenalidomide and CC-4047 inhibit the pro- liferation of malignant B cells while expand- ing normal CD34+ progenitor cells. Cancer Res. 2007;67(2):746-755.
37. Boddu P, Kantarjian H, Garcia-Manero G, Allison J, Sharma P, Daver N. The emerging role of immune checkpoint based approach- es in AML and MDS. Leuk Lymphoma. 2018;59(4):790-802.
38. Hidalgo-Lopez JE, Kanagal-Shamanna R, Quesada AE, et al. Progress in myelodysplas- tic syndromes: clinicopathologic correlations and immune checkpoints. Clin Lymphoma Myeloma Leuk. 2017;17s:S16-S25.
1364
haematologica | 2019; 104(7)